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Pardiac Expression of Placental
rowth Factor Predicts the Improvement
f Chronic Phase Left Ventricular Function
n Patients With Acute Myocardial Infarction
ajime Iwama, MD, Shiro Uemura, MD, Noriyuki Naya, BS, Kei-ichi Imagawa, PHD,
asuhiro Takemoto, MD, Osamu Asai, MD, Kenji Onoue, MD, Satoshi Okayama, MD,
atoshi Somekawa, MD, Yoshitomi Kida, MD, Yukiji Takeda, MD, Kimihiko Nakatani, MD,
inoru Takaoka, MD, Hiroyuki Kawata, MD, Manabu Horii, MD, Tamio Nakajima, MD,
aofumi Doi, MD, Yoshihiko Saito, MD
ashihara, Nara, Japan
OBJECTIVES Our aim was to investigate cardiac expression of placental growth factor (PlGF) and its
clinical significance in patients with acute myocardial infarction (AMI).
BACKGROUND Placental growth factor is known to stimulate wound healing by activating mononuclear cells
and inducing angiogenesis. The clinical significance of PlGF in AMI is not yet known.
METHODS Fifty-five AMI patients and 43 control subjects participated in the study. Peripheral blood
sampling was performed on days 1, 3, and 7 after AMI. Blood was also sampled from the
coronary artery (CAos) and the coronary sinus (CS), before and after acute coronary
recanalization. Cardiac expression of PlGF was analyzed in a mouse AMI model.
RESULTS In AMI patients, peripheral plasma PlGF levels on day 3 were significantly higher than in
control subjects. Plasma PlGF levels just after recanalization were significantly higher in the
CS than the CAos, which indicates cardiac production and release of PlGF. Peripheral
plasma levels of PlGF on day 3 were negatively correlated with the acute phase left ventricular
ejection fraction (LVEF), positively correlated with both acute phase peak peripheral
monocyte counts and chronic phase changes in LVEF. Placental growth factor messenger
ribonucleic acid expression was 26.6-fold greater in a mouse AMI model than in sham-
operated mice, and PlGF was expressed mainly in endothelial cells within the infarct region.
CONCLUSIONS Placental growth factor is rapidly produced in infarct myocardium, especially by endothelial
cells during the acute phase of myocardial infarction. Placental growth factor might be
over-expressed to compensate the acute ischemic damage, and appears to then act to improve
LVEF during the chronic phase. (J Am Coll Cardiol 2006;47:1559–67) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.064American College of Cardiology Foundation
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tfter acute myocardial infarction (AMI), reducing the total
mount of necrotic myocardium and minimizing ventricular
emodeling are the most effective ways of preserving long-term
eft ventricular function and improving prognosis (1). In that
egard, a variety of cytokines and circulating cells are known to
articipate in the wound healing processes that are ongoing in
he injured myocardium of the post-myocardial infarction
eart, and it has been suggested that appropriate manipulation
f those molecules and/or cells could be used to exert a
eneficial effect that promotes long-term improvement of
ardiac function after AMI (2–4).
Recent progress in stem cell research has opened the
ossibility of regenerating lost cardiomyocytes and/or vascular
issue by recruiting autologous bone-marrow-derived stem cells
o the heart after AMI. Among the candidate cytokines
onsidered for this purpose, vascular endothelial growth factor
VEGF) has been extensively studied because of its established
ngiogenic capacity and its ability to mobilize endothelial
rogenitor cells (5). Vascular endothelial growth factor is
From the First Department of Medicine, Nara Medical University, Kashihara,
ara, Japan.A
Manuscript received December 17, 2004; revised manuscript received October 26,
005, accepted November 8, 2005.nown to be strongly expressed in the ischemic myocardium,
nd treatment with exogenous VEGF has been clearly dem-
nstrated to enhance vessel formation in ischemic myocardium
6,7). Still, in vivo treatment with VEGF gene or recombinant
EGF protein does not always lead to improved ventricular
unction because of the development of non-functioning or
nstable capillary vessels (8,9).
Placental growth factor (PlGF) is a member of the
EGF family that acts via VEGF receptor-1 (flt-1) (10,11).
ike VEGF, PlGF has been shown to play a key role in
ascular development under pathological conditions; for
nstance, by stimulating both angiogenesis and arteriogen-
sis, PlGF enhances not only capillary but also collateral
ormation in ischemic tissue (12). In addition, PlGF appears
o promote mobilization of flt-1-positive hematopoietic
tem cells that might be involved in regeneration of vessels
nd myocardium from bone marrow to the peripheral
irculation (13,14).
With that as background, our aim in the present study
as to assess cardiac expression of PlGF in both human
MI patients and a mouse model of AMI, and to determine
he impact of PlGF expression on the clinical features of
MI in humans.
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linical study. PATIENT POPULATION. Fifty-five patients
dmitted to Nara Medical University Hospital with AMI were
nrolled in this study. In addition, 43 age-matched healthy
ubjects (mean age 62.7  1.5 years, 33 men, 10 women)
erved as control subjects. Acute MI was diagnosed when
atients experienced chest pain within 24 h before admission
nd lastedmore than 30min and was not relieved by sublingual
itroglycerin, and exhibited ST-segment elevation and/or ab-
ormal Q waves on an electrocardiogram and elevated serum
reatine kinase (CK) levels. Exclusion criteria were AMI more
han 24 h from the onset, a history of renal dysfunction
equiring dialysis, evidence of malignant disease, or an unwill-
ngness to participate. All patients received coronary angiogra-
hy on admission. When patients had an occluded coronary
rtery suitable for percutaneous coronary intervention (PCI)
sing coronary stents, the patients underwent emergency PCI.
fter PCI, patients underwent left ventriculography to assess
he left ventricular ejection fraction (LVEF) in acute phase.
hen they were routinely treated with heparin, isosorbide
initrate, nicorandil, ticlopidine, aspirin, and an angiotensin-
onverting enzyme inhibitor or angiotensin II receptor blocker.
The protocol was approved by our institutional ethics
ommittee (#2002–009, Nara Medical University Ethics
ommittee), and written informed consent was obtained in
ll of cases from either the patient or his/her family
embers.
LINICAL PARAMETERS OF AMI PATIENTS. The clinical pa-
ameters assessed included age, gender, and coronary risk
actors (smoking, hypertension, diabetes mellitus, hyperlip-
demia, and obesity). The diagnostic criteria for the coro-
ary risk factors were as follows: hypertension, blood pres-
ure more than 140/90 mm Hg, and/or a history of taking
ntihypertensive medication; diabetes mellitus, fasting
lasma glucose more than 126 mg/dl, or casual plasma
lucose more than 200 mg/dl, or a diabetic pattern in 75 g
GTT; hyperlipidemia, serum total cholesterol levels of
220 mg/dl or serum triglyceride levels of 150 mg/dl;
besity, body mass index of more than 25 kg/m2. Infarct
ite, peak CK, peak CK-MB, LVEF, and coronary angio-
raphical findings were selected for analysis as indicators of
Abbreviations and Acronyms
AMI  acute myocardial infarction
CAos  coronary artery ostium
CK  creatine kinase
CS  coronary sinus
flt-1  vascular endothelial growth factor receptor-1
IR  ischemia-reperfusion
LVEF  left ventricular ejection fraction
MI  myocardial infarction
PCI  percutaneous coronary intervention
PlGF  placental growth factor
VEGF  vascular endothelial growth factorI severity. cLOOD SAMPLING AND ANALYSIS. Peripheral blood samples
ere collected from all subjects upon admission and then on
he third and seventh hospital days. In 30 patients, more-
ver, blood was sampled during emergency cardiac cathe-
erization from the coronary artery ostium (CAos) and
oronary sinus (CS) using a 4-F coronary catheter (Good-
an, Tokyo, Japan) and a 6-F CS catheter (Goodman,
okyo, Japan) before and 30 to 45 min after emergency
CI. Plasma samples were collected in EDTA anticoagu-
ant tubes and stored at 80°C until assayed.
White blood cell counts, profiles, and peripheral blood
onocyte counts were obtained using Sysmex SE9000
Sysmex, Kobe, Japan). Blood biochemistry data were ob-
ained using commercially available assays.
Levels of PlGF and VEGF were measured using com-
ercially available enzyme-linked immunoadsorbent assay
its (DPG00, DVE00, respectively; R&D Systems, Min-
eapolis, Minnesota). This enzyme-linked immunoadsor-
ent assay kit also cross-reacts with human recombinant
lGF-2 isoform (50%) and also reacts with human recom-
inant VEGF/hrPlGF heterodimer (5%). For peripheral
lood samples, maximum values on the day of admission
nd on the third and seventh hospital days were considered
o be the peak levels for each cytokine at those times.
NALYSIS OF CORONARY ANGIOGRAPHY AND LEFT VEN-
RICULOGRAPHY. Coronary angiograms and left ventricu-
ograms were analyzed by two independent angiographers
ithout knowledge of the patients’ background. Antegrade
ow in the infarct-related coronary artery at the initial
xamination, after recanalization and during follow-up, was
raded according to the Thrombolysis in Myocardial Infarc-
ion classification (15). Global LVEF was obtained from the
ight anterior oblique projection of contrast left ventriculogra-
hy (QLV-CMS; MEDIS, Leiden, the Netherlands).
xperimental study. MOUSE MODEL OF AMI. After anes-
hetizing 10- to 12-week-old male mice (C57BL/6, SLC,
amamatsu, Japan) using isoflurane with artificial ventila-
ion, thoracotomy was performed in the left intercostal
pace, and a proximal site of the left coronary artery was
igated as described previously (16). The duration of coro-
ary artery ligation was 40 or 60 min in the ischemia-
eperfusion (IR) model, and permanent ligation in the MI
odel. Mice were sacrificed under general anesthesia with
entobarbital, and the heart was excised on days 3 and 7
fter surgery in the IR model and on days 1, 3, 7, and 28
fter surgery in the MI model.
UANTITATIVE REAL-TIME POLYMERASE CHAIN REAC-
ION. Frozen infarct heart tissue, excised on day 3 after
urgery, was homogenized in Trizol reagent (Invitrogen
orp., Carlsbad, California) using the standard protocol.
fter DNase processing, PIGF cDNA was synthesized
sing Superscript II reverse transcriptase (Invitrogen Corp.).
elative PIGF mRNA levels were then determined using
eal-time polymerase chain reaction carried out using
DNA samples with Assay-on-Demand Product, Taqman
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April 18, 2006:1559–67 Impact of PlGF on the Improvement of LVEF in AMIrobe and an ABI Prism 7700 Sequence Detection System
ABI, PE Biosystems, Foster City, California). Levels of
IGF mRNA were normalized to those of glyseraldehyde-
-phosphate dehydrogenase mRNA.
MMUNOHISTOCHEMICAL AND IMMUNOFLUORESCENT
TAINING OF PLGF IN INFARCT MYOCARDIUM. The left
entricular apex, including the infarct lesion, was perfused
ith 4% paraformaldehyde and harvested, then cut into
-m sections followed by immersion fixated in 4% para-
ormaldehyde for overnight. The sections were labeled with
rimary mouse anti-PlGF (AF465 1:100 dilution, R&D
ystems) and then with secondary biotin-labeled anti-gout
gG (BA-9500 1:800 dilution; Vector Laboratories, Burlin-
ame, California) antibodies, and processed using the
BC-DAB (3,3=-diaminobenzidine tetrahydrochloride)
ethod (Vectastain Elite ABC Kit, Vector Laboratories).
ematoxylin was used for nuclear staining.
For immunofluorescent staining, acetone-fixed sections
ere incubated for 1 h at room temperature with a primary
nti-PlGF (sc-1882, 1:100 dilution, Santa Cruz Biotechnol-
gy Inc., Santa Cruz, California) and/or fluorescein
sothiocianate-conjugated anti-alpha-smooth muscle actin
F3777, 1:400 dilution, Sigma-Aldrich Inc., St. Louis, Mis-
ouri) and/or anti-von Willebrand factor (A0082, 1:200 dilu-
ion, DakoCytomation Corp., Carpinteria, California) and/or
iotin-labeled anti-mouse CD11b (13-0112, eBioscience, San
iego, California). After washing, the sections were incubated
or 30 min at room temperature with Cy3-conjugated donkey
nti-goat IgG (705-165-003, Jackson Immunoresearch Labo-
atories, Inc., West Grove, Pennsylvania) for PlGF and/or
nti-rabbit IgG (A21441, Molecular Probes Inc., Eugene,
regon) for von Willebrand factor and/or Cy2-conjugated
nti-biotin (016-220-084, Jackson Immunoresearch Laborato-
ies Inc.) for CD11b. 4',6-Diamidino-2-phenylindole was used
or nuclear staining.
EASURING THE BLOOD VESSEL DENSITY IN THE INFARCT
YOCARDIUM. We quantified the blood vessel density in
he MI and IR models in mice sacrificed on day 7 after
urgery. Sliced sections with 3 m thick of the left ventricle,
ncluding the infarct lesion, were labeled with mouse anti-
lpha-smooth muscle actin (monocronal anti-actin, alpha-
mooth muscle-alkaline phosphatase antibody produced in
ouse clone 1A4) (A5691, 1:200 dilution, Sigma-Aldrich
nc.) and processed using 5-bromo-4-chloro-3-indoxyl
hosphate/nitro blue tetrazolium chloride substrate (K0598,
akoCytomation Corp.) for measuring the blood vessel
ensity in the marginal area of infarct myocardium. Blood
essels were counted in a stained slide from at least 10
andomly selected fields under 400 confocal microscopy
AX70, OLYMPUS, Tokyo, Japan) and expressed as count
er high power field.
tatistical analysis. Continuous data are expressed as means
SE. Comparisons between control and AMI groups were
ade using paired or unpaired t tests, as appropriate. To assess
orrelations between two parameters, simple linear regressions
f
Rere calculated using the least squares method. Values of p 
.05 were considered significant. The relationship between the
mprovement of LVEF and clinical baseline parameters in-
luding PlGF were analyzed using simple and multiple linear
egression analysis. All statistics were calculated using Stat
iew for Windows, version 5.0 (SAS Institute Inc., Cary,
orth Carolina).
ESULTS
atient characteristics. Among the 55 enrolled patients,
9 received follow-up cardiac catheterization six months
fter the onset of AMI. Of the 16 patients who did not
eceive follow-up cardiac catheterization, 3 died during
ospitalization because of pump failure, 5 were transferred
o other hospitals, and 8 refused a follow-up examination.
able 1 shows the clinical characteristics of the AMI
atients participating in this study. There were 43 men and
2 women with a mean age of 66.7  1.8 years (range, 31
o 88 years). The mean interval from the onset of AMI to
eperfusion was 10.8  1.8 h. The mean value of the
aximum CK level was 4,117 502 IU/l, and mean LVEF
uring the acute phase was 57.1  1.7%. The mean peak
onocyte count was 702  40 cells/l, which was appar-
ntly unrelated to the severity of the AMI estimated from
he LVEF and maximum CK levels. The mean interval
rom admission to the peak monocyte count was 3.2  0.1
ays.
hanges in peripheral plasma PlGF levels after AMI. When
easured in peripheral plasma obtained on the 1st, 3rd, and
th days after the onset of AMI, levels of both PlGF and
EGF were found to peak on day 3 after AMI in most
ases, at which time they were significantly higher than in
ontrol subjects (Fig. 1A). They then tended to decline
bout one week after AMI (data not shown).
able 1. Clinical Characteristics of AMI Patients
ge (yrs) 66.7  1.8
ender (male/female) 43/12
eperfusion time (h) 10.8  1.8
ax CK (IU/l) 4,117  502
ax CK-MB (IU/l) 274  34
VEF at the onset of MI (%) 57.1  1.7
eak WBC counts (cells/l) 11,158  494
eak PBMC (cells/l) 702  40
ulprit lesion
LAD 27
LCx 4
RCA 24
oronary risk factor
Diabetes 23
Hypertension 29
Hyperlipidemia 35
Smoking 25
Obesity 7
ata are expressed as mean value  SE.
AMI  acute myocardial infarction; CK  creatine kinase; LAD  left anterior
escending artery; LCx  left circumflex artery; LVEF  left ventricular ejection
raction; Max  maximum; MI  myocardial infarction; PBMC  peripheral blood;
CA  right coronary artery; WBC  white blood cell.
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Impact of PlGF on the Improvement of LVEF in AMI April 18, 2006:1559–67lasma PlGF levels in the coronary circulation during
MI. To determine whether the elevated PlGF levels in the
eripheral blood plasma reflected release of the cytokine from
he infarct heart, we measured PlGF levels in plasma samples
ollected from the CAos and CS at the time of emergency
oronary intervention (Fig. 1B). Before reperfusion of the
nfarct-related artery, PlGF levels were similarly low in the
Aos and CS (20.2  3.1 pg/ml and 18.4  2.7 pg/ml,
espectively), and were comparable to the levels in healthy
ubjects. After reperfusion, however, PlGF levels in both the
Aos and CS were significantly elevated, and the levels in the
S were significantly higher than those in the CAos (90.1 
.8 pg/ml vs. 79.7 7.6 pg/ml; p 0.01), which is indicative
igure 1. (A) Peripheral blood plasma cytokine levels in patients with acute
yocardial infarction (AMI). Placental growth factor (PlGF) and vascular
ndothelial growth factor (VEGF) were significantly higher than control in
lood samples from AMI patients. Bars represent means  SE. (B)
lacental growth factor levels in plasma samples taken from the coronary
rtery ostium (CAos) and coronary sinus (CS) before and just after
ercutaneous coronary intervention. Before recanalization (RC) of an
nfarct-related artery, plasma PlGF levels were similarly low in the CAos
nd CS. After RC, PlGF levels were significantly increased in both the
Aos and CS, as compared to before RC, and levels in the CS were
ignificantly higher than in the CAos. Closed circles and bars represent
eans  SE.f cardiac production and release of PlGF.
Dlinical determinants of plasma PlGF levels. To identify
he clinical determinants governing the plasma PlGF levels,
e evaluated the relationship between plasma PlGF levels
nd the clinical characteristics of our patients. We found
hat plasma PlGF levels were unaffected by gender or by the
resence or absence of any of the coronary risk factors
Table 2). Likewise, age, the extent of coronary atheroscle-
osis, site of the culprit lesion, reperfusion time, and
aximum CK did not correlate with plasma PlGF levels
data not shown).
linical significance of PlGF during AMI. Plasma PlGF
evels on day 3 post-MI positively correlated with peak
onocyte counts (r  0.415, p  0.0016), but did not
orrelate with total peripheral white blood cell counts,
uggesting PlGF may be involved in the peripheral mobi-
ization of mononuclear cells during AMI. By contrast,
lasma VEGF levels on day 3 post-MI did not correlate
ith either the total white blood cell counts or the monocyte
ounts (Fig. 2). At the same time, plasma PlGF levels
egatively correlated with acute phase LVEF (r  0.434,
 0.021), though plasma VEGF levels did not (Figs. 3A
nd 3B). In addition, plasma PlGF levels on day 3 post-MI
ere positively correlated with the subsequent changes in
VEF observed during the chronic phase 6 months after the
nset of AMI (EF, R 0.38, p 0.0196; Fig. 3C), which
eflects improvement in left ventricular function. The cor-
esponding VEGF levels did not correlate with EF (Fig.
D). Multiple regression analysis revealed that the plasma
lGF level was the strongest independent predictor of
mprovement of LVEF during the chronic phase (p 
.0098) (Table 3). Furthermore, when we studied the
ubgroup of patients with substantially impaired left ven-
ricular function (LVEF 60%), we found that patients
ho showed improvement in LVEF (LVEF 0) (n 
3), as LVEF 0, in the chronic phase had significantly
igher plasma PlGF levels than patients without improvement
n LVEF (LVEF0) (n 8) (47.3 22.6 pg/ml vs. 27.9
2.6 pg/ml, respectively), supporting that peak PlGF levels in
he acute phase, independent from baseline LVEF, is the
eterminant factor for the improvement of LVEF in the
hronic phase. Placental growth factor might be over-expressed
o compensate for ischemic damage during AMI.
able 2. Plasma PlGF Levels on Third Day After AMI and the
oronary Risk Factors
Risk Factors
PlGF (pg/ml)
p Value() ()
iabetes 31.4  21.2 37.8  29.8 NS
ypertension 35.9  28.2 33.7  23.7 NS
yperlipidemia 33.4  23.2 37.0  30.1 NS
moking 31.8  20.3 37.8  30.8 NS
besity 26.1  8.7 36.4  28.0 NS
Male Female p Value
31.1  3.0 40.7  11.4 NSata are expressed as mean value  SE.
AMI  acute myocardial infarction; PlGF  placental growth factor.
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April 18, 2006:1559–67 Impact of PlGF on the Improvement of LVEF in AMIxpression of PlGF in a mouse AMI model. To confirm
he augmented production of PlGF in infarct hearts, we
ssessed the expression of PlGF mRNA in a mouse model
f MI. We found that levels of PlGF transcript were
ncreased 26.6-fold (p  0.0001) in infarct hearts of MI
odels, as compared to sham-operated hearts, on days 1
nd 3 post-MI, and that transcript levels had returned to
ontrol levels on days 7 and 28 post-MI (Fig. 4).
Immunohistochemical analysis with confocal micros-
opy (AX70, OLYMPUS) showed that PlGF protein was
trongly expressed in vascular tissues, especially vascular
ndothelial cells of both capillaries and small vessels in
igure 2. Relationship between plasma placental growth factor (PlGF) lev
ounts. Neither PlGF (A) nor vascular endothelial growth factor (VEGF)
ositively correlated with peak monocyte counts (C), though VEGF level
igure 3. Relationship between plasma placental growth factor (PlGF) leve
uring the acute phase. Whereas plasma PlGF levels negatively correlated
ascular endothelial growth factor (VEGF) levels did not (B). Plasma PlGF leve
hanges of left ventricular EF (EF) that occurred between the acute and chrohe infarct myocardium (Fig. 5), within the infarct
yocardium, but was scarcely detected in non-infarct
egions, and was not detected at all in sham-operated
earts (data not shown). Although we cannot totally deny
he PlGF expression in vascular smooth muscle cell in the
ame vessel, results from double immunofluorescent
taining indicate that endothelial cells of vascular tissue
n infarct myocardium is the major site of PlGF produc-
ion (Fig. 6). We also found a small number of PlGF-
ositive cells in interstitial space in infarct myocardium.
owever, PlGF-positive cells did not cross-react with
nown macrophage antibody (anti-CD11b) (Fig. 6).
day 3 post-myocardial infarction and peripheral white blood cell (WBC)
rrelated with total peripheral WBC counts. Placental growth factor levels
not (D). PBMC  peripheral blood.
day 3 post-myocardial infarction and left ventricular ejection fraction (EF)
left ventricular EF at the onset of acute myocardial infarction (A), plasmaels onls on
withls on day 3 post-myocardial infarction were positively correlated with the
nic phases (C); VEGF levels were not (D).
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Impact of PlGF on the Improvement of LVEF in AMI April 18, 2006:1559–67Next, we evaluated the effect of severity of ischemia on
he PlGF mRNA expression and the angiogenesis in isch-
mic myocardium. Placental growth factor mRNA expres-
ion on day 3 after surgery did not increase in mice with
0-min ischemia, but significantly increased in the 60-min
schemia model (1.9-fold increase), as well as in the MI
odel (26.6-fold increase) compared with sham-operated
ice. Furthermore, PlGF mRNA expression levels were
ignificantly higher in MI than in IR. Blood vessel densities
n the marginal area of infarct myocardium were also
ignificantly increased in both IR and MI models compared
ith sham, and blood vessel density of the MI model was
ignificantly higher (2.5-fold increase) compared with the
R model (Fig. 7B).
ISCUSSION
he present study demonstrates for the first time that:
) cardiac production of PlGF is increased after AMI; 2) the
ajor site of augmented expression of PlGF is the endo-
helium of vessels within the infarcted region; 3) PlGF
roduction after AMI is determined, in part, by the amount
f injured myocardium; and 4) plasma PlGF levels on day 3
ost-MI are positively correlated with both the circulating
onocyte counts during the acute phase and the degree of
mprovement of LVEF during the chronic phase of MI.
aken together, these findings may suggest that cardiac
xpression of PlGF has a beneficial effect on wound healing
rocesses after AMI, possibly by inducing peripheral mobi-
ization of mononuclear cells and enhancing angiogenesis.
ardiac expression of PlGF during AMI. Earlier studies
howed that PlGF is expressed in placental tissue, tropho-
lasts, leukocytes, and endothelial cells under normal phys-
ological conditions (17–19). The present findings indicate
hat, during AMI, vascular tissue, especially the endothe-
ium within the infarct myocardium, is also a major site of
lGF production. Clinically, we found that LVEF during
he acute phase is negatively correlated with plasma PlGF
evels on day 3 post-MI, making it likely that the degree of
njury to the vascular endothelium within the infarct myo-
ardium is a key determinant of cardiac PlGF production
fter AMI. Furthermore, our observation that induction of
lGF begins very early (within 24 h) after the onset of
ardiac ischemia and is sustained for about a week thereafter
uggests that tissue PlGF is importantly involved in the
able 3. Multiple Regression Analysis for Chronic Phase Left
entricular Function
Clinical Parameters p Value
PlGF 0.05
Age NS
Max CK NS
Max CK-MB NS
Reperfusion time NS
ata are expressed as mean value  SD.
CK  creatine kinase; Max  maximum; PlGF  placental growth factor.arly phase of tissue healing after ischemic injury (e.g.,
m
cngiogenesis). Although the signaling pathway leading to
p-regulation of PlGF expression in the ischemic myocar-
ium is not yet clear, expression level of PlGF mRNA levels
as regulated by the degree and duration of myocardial
schemia in this study. Supporting our observations, one in
itro study reported that PlGF is induced by hypoxia (20).
n that regard, the promoter region of the PlGF gene does
ot contain a hypoxia-inducible, factor-responsive element,
ut it does contain other hypoxia-responsive elements, such
s those for metal transcription factor-1 and Sp-1 (20,21). It
s, thus, plausible that hypoxia is an important stimulus of
lGF expression within the infarct myocardium.
Although their study population and the study design are
ot the same with the present study, Heeschen et al. (22)
ave reported that plasma levels of PlGF in patients with
on–ST-segment elevated MI and refractory unstable an-
ina pectoris were significantly elevated compared with
ealthy control subjects, supporting that prolonged and/or
evere ischemia induces the cardiac expression of PlGF.
linical significance of PlGF during healing after AMI. The
unction of PlGF after AMI has not been systematically
tudied. We noticed, however, that patients with higher
lasma PlGF levels on day 3 post-MI showed greater
mprovement in LVEF during the chronic phase (6 months
ost-MI) than patients with lower plasma PlGF levels, and
lso that patients with improvement in LVEF in the chronic
hase had significantly higher plasma levels of PlGF in the
cute phase compared with patients without improvement,
gain suggesting the involvement of PlGF in the healing of
he injured myocardium. Thus, PlGF might be over-
xpressed to compensate the ischemic damage during AMI.
ike VEGF, PlGF is known to have powerful angiogenic
roperties, especially under pathological circumstances, such
igure 4. Expression of placental growth factor (PlGF) mRNA in the
earts of mice subjected to myocardial infarction induced by coronary
rtery ligation. Quantitative real-time polymerase chain reaction revealed
hat expression of PlGF mRNA was significantly up-regulated in infarct
earts, as compared to sham-operated hearts on days 1 and 3 post-
yocardial infarction, but had returned to levels that did not differ from
ontrol by days 7 and 28. AMI  acute myocardial infarction.
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April 18, 2006:1559–67 Impact of PlGF on the Improvement of LVEF in AMIs in cancer and limb ischemia (23,24). This suggests that,
n cases of AMI, locally expressed PlGF might directly
timulate angiogenesis in both the infarct and infarct-border
egions. In mouse experiments of our study, we observed
hat both temporal and permanent occlusion of coronary
rtery promoted PlGF gene expression, as well as angiogen-
sis in ischemic myocardium. As shown in Figure 7, the
ncrement of vessel density and PlGF expression in the
ermanent occlusion model was substantially higher than
hat in temporal ischemia. Accordingly, cardiac PlGF ex-
ression seems to be involved in the angiogenesis under the
igure 5. Photomicrographs showing immunohistochemical staining of
A) Infarct myocardium (original magnification, 60). (B and C) Higher
xpression of placental growth factor protein in the endothelium within t
bsence of placental growth factor protein in the non-infarct area (D). Ar
igure 6. Photomicrographs showing immunofluorescent staining of a sm
taining of the target vessel with anti-placental growth factor (red) and anti
rowth factor expression within vascular endothelial cells. (B) Combination
ctin (green) antibodies. Note that placental growth factor expression is
nti-placental growth factor (red) and anti-CD11b (green) antibodies. Placental
D11b-positive cell (macrophage). Original magnification, 800. DAPI was uituation of severe myocardial ischemia. Moreover, we
bserved that plasma PlGF levels on day 3 post-MI were
ignificantly correlated with peak monocyte counts 3.2 
.1 days post-MI, suggesting that PlGF released from the
nfarct heart exerts a stimulatory effect on monocyte mobi-
ization. Consistent with that idea, Hattori et al. (13) observed
n increase in circulating stem cells after adenovirus-mediated
ene transfer of PlGF to BALB/c mice (14). They suggested
hat PlGF induces stem cell mobilization via flt-1, which is
xpressed on monocyte, CD34 cells, and hematopoietic
tem cells (25). Furthermore, recent observations by Pipp et
tal growth factor in mouse heart on day 3 post-myocardial infarction.
ification (240) of the corresponding box (A). The staining shows strong
arct region (B), as well as in interstitial cells (C). The staining shows an
indicate vascular tissue, arrowheads interstitial cells.
ery and infiltrating cell within the infarct myocardium. (A) Combination
illebrand factor (green) antibodies. Yellow coloration indicates placental
ing with anti-placental growth factor (red) and anti-alpha-smooth muscle
icted to the intima of the target vessel. (C) Combination staining withplacen
magnall art
-von W
stain
restr-growth-factor-expressing cell in the interstitium did not cross-react with
sed for nuclear staining (blue).
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Impact of PlGF on the Improvement of LVEF in AMI April 18, 2006:1559–67l. (26) indicate that, in animal ischemic limb models, PlGF
dministration significantly enhances collateral vessel for-
ation by activating and recruiting mononuclear cells to the
schemic region in an flt-1–dependent fashion. We specu-
ate that same mechanisms might work in MI. It has also
een reported that monocytes infiltrating into the injured tissue
irectly stimulate collateral vessel growth by releasing various
igure 7. Placental growth factor (PlGF) gene expression and angiogenesis
n ischemic myocardium. (A) Relation between the duration of ischemia
nd the PlGF gene expression three days after surgery in mouse models of
yocardial infarction (MI, as permanent occlusion) and ischemia-
eperfusion (IR). Bars represent PlGF mRNA levels of infarct heart tissue.
lacental growth factor mRNA expression levels were significantly in-
reased in both in 60 min. Ischemia-reperfusion and MI models compared
ith sham operated mice. (B) Relation between the duration of ischemia
nd the blood vessel density in the marginal area of infarct myocardium in
ouse models of MI and IR. Heart tissue was sampled seven days after
urgery. Bars represent alpha-smooth muscle actin-positive blood vessel
ounts in infarct lesion per field under 400 microscopy. Blood vessel
ensities in both MI and IR are significantly increased compared with
ham, and blood vessel density in MI is significantly higher (2.5)
ompared with IR. *p 0.001 for MI and IR vs. sham; **p 0.001 for MI
s. IR; ***p  0.01 for IR 60 min vs. sham.ytokines, including basic fibroblast growth factor and mono- vyte chemoattractant protein-1 (27), which is consistent with
he idea that, in addition to its direct angiogenic activity,
lGF facilitates wound healing by helping home circulating
ononuclear and bone marrow-derived stem cells to the
njured myocardium by inducing the expression of adhesion
olecules on the surfaces of both endothelial and mononu-
lear cells (28). Furthermore, macrophage is also known to
xpress flt-1, so elevated PlGF might enhance wound
ealing by activating and recruiting macrophages that have
mportant roles in removing necrotic tissue from an injured
rea (27,29).
A crucial consideration when interpreting the results of
he present study is to determine whether plasma PlGF
evels in the range of 30 to 120 pg/ml, which were the
ighest concentrations observed in our AMI patients, are
ufficient to exert a biological effect, such as angiogenesis or
obilization of mononuclear cells from bone marrow. It is
oteworthy in that regard that an earlier report showed that
lGF at a concentration of 100 pg/ml stimulates DNA
ynthesis in flt-1–expressing endothelial cells (30), which
uggests that the plasma PlGF levels we observed in our
atients were indeed sufficient to be biologically active.
ifferences between PlGF and VEGF. We found that,
ike PlGF, plasma VEGF levels were elevated in patients’
lood, but they did not correlate with either monocyte
ounts or improvement in LVEF. One possible explanation
or the difference between these two angiogenic cytokines is
hat PlGF only binds to flt-1, whereas VEGF binds to both
t-1 and VEGF receptor 2 (31). Another possible explana-
ion is that flt-1–mediated intracellular signaling is ligand-
pecific. For example, PlGF-mediated stimulation of flt-1
nduces MAP kinase activation in porcine aortic endothelial
ells, which, in turn, leads to enhanced DNA synthesis (30).
y contrast, VEGF-mediated stimulation of flt-1 does not
ctivate the MAP kinase pathway (30).
linical implications. Blood vessel growth is a principle
omponent of the wound healing process. Recently, admin-
stration of bone marrow-derived or peripheral blood-
erived mononuclear cells into infarct-related coronary ar-
eries was shown to improve left ventricular function by
nhancing angiogenesis and regeneration of the myocar-
ium (32–34). Similarly, Hojo et al. (35) reported that
atients showing improved left ventricular systolic function
fter MI exhibited significantly higher monocyte counts
han patients without improvement. We, therefore, suggest
hat an efficient and safe method for mobilizing bone
arrow mononuclear cells may be a useful approach to
reating AMI. Our finding that local expression of PlGF is
ssociated with increased monocyte counts and improved
VEF after AMI suggests administration of human PlGF
ight be a possible means of improving left ventricular
unction in the chronic phase. On the other hand, several
tudies have reported a negative relationship between mono-
yte counts and long-term prognosis after AMI (22,36,37),
hich suggests peripheral monocytosis may also have ad-
erse effects. Additional studies analyzing the relation be-
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April 18, 2006:1559–67 Impact of PlGF on the Improvement of LVEF in AMIween PlGF levels and monocyte counts during the acute
hase of MI and subsequent left ventricular function and
ong-term prognosis in MI patients are needed to address
his issue.
onclusions. Placental growth factor is rapidly produced
n infarct myocardial tissue, especially in the endothelium of
essels within the infarct myocardium during the acute
hase of MI. The resultant elevation in plasma PlGF levels
ppears to contribute to the improved LVEF seen during
he chronic phase, probably by activating monocytes and
nhancing angiogenesis.
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